BTG And SciClone Say DC Bead Gets Approved By China FDA - Quick Facts

(RTTNews) - BTG plc (BTG.L) a specialist healthcare company, and its partner SciClone Pharmaceuticals, Inc. (SCLN) Thursday said the China Food and Drug Administration has approved the registration of DC Bead for the embolisation of malignant hypervascularised tumours. Earlier, BTG had granted SciClone exclusive licensing and distribution rights to DC Bead in China. As per the deal, SciClone will buy product from BTG at a specified price for sale in China.

DC Bead, a treatmentfor liver cancer, is currently approved in 40 countries worldwide, including Europe. However, it is not currently cleared by the FDA for sale or distribution in the USA.